Aluminium and alzheimer’s disease: Review of possible pathogenic mechanisms

Dementia and Geriatric Cognitive Disorders

Volumn 7, Issue 1, 1996, Pages 1-9

  Armstrong, R A ^a   Winsper, S J ^a   Blair, J A ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Aluminium; Alzheimer s disease; Amyloid precursor protein; Immune reaction; Tau

Indexed keywords

ALUMINUM; AMYLOID PRECURSOR PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN CELL; HISTOCOMPATIBILITY COMPLEX; HUMAN; IMMUNITY; LONG TERM EXPOSURE; NEUROFIBRILLARY TANGLE; NEUROPIL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN VARIANT; REVIEW; SENILE PLAQUE;

ALUMINUM; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; HUMANS; TAU PROTEINS;

EID: 0030069372     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000106845     Document Type: Article

References (107)

1. Hardy JA, Higgins GA: Alzheimer's disease: The amyloid cascade hypothesis. Science 1992; 256:1S4-1S5.
2. Chartier-Harlin M-C, Crawford F, Houlden H, Warren A, Hughes D, Fidani L, Goate A, Ros-sor M, Rocques P, Hardy J, Mullan M: Early onset Alzheimer's disease caused by mutations at codon 717 of the [5-amyloid precursor gene. Nature 1991:353:844-846.
3. Goate R, Chartier-Harlin M-C, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rookc K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704-706.
4. Murrell J, Farlow M, Ghetli B, Benson MD: A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 1991;254:97-99.
5. Schellcnberg GD, Bird TD, Wijsman EM, Orr HT, Anderson L, Nemens E, White JA, Bonny-casle L, Weber JL, Alonso ME, Poller H, Heston LL, Martin GM: Genetic linkage evidence for a familial Alzheimcrs’s disease locus on chromosome 14. Science 1992;258:668-671.
6. Bird TD, Lampe TH, Nemens EJ, Miner GW, Sumi SM, Schellenberg GD: Familial Alzheimer’s disease in American dcsccndcnts of the Volga Germans: Probable genetic founder effect. Ann Neurol 1988;23:25-31.
7. Harrison P: Alzheimer’s disease and chromosome 14: Different gene, same process? Br J Psychiatry 1992:163:2-5.
8. Mullan M, Crawford F: Genetic and molecular advances in Alzheimer's disease. Trends Ncu-rosci 1993;16:398-403.
9. Tanzi RE, Vaula G, Romano DM, Mortilla M, Huang TL: Assessment of amyloid p protein precursor gene mutations in a large set offamil-ial and sporadic Alzheimer's disease cases. Am J Hum Genet 1992:51:273-282.
10. Saunders AM, Strittmatter WJ, Schmechcl D, St George-Hyslop PH, Pcrivak-Vance MA, Joo SH, Rosi BL, Gusclla JF, Crapper-Maclachlan DR, Alberts MJ: Association of apolipoprotein E altelle e4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993:43: 1467-1472.
11. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesan GS, Perivak-Vance M, Schmechcl D, Saunders AM, Goldgaber D, Roses AD: Binding of human apolipoprotein E to synthetic amyloid-S-peptide: Isoform-spe-cific effects and implications for latc-onsct Alzheimer’s disease. Proc Natl Acad Sci USA 1993:90:8098-8102.
12. Chadwick DJ, Whelan J (eds): Aluminium in Biology and Medicine. Ciba Foundation Symp 169. New York. Wiley, 1992.
13. Doll R: Alzheimer's disease and environmental aluminium. Age Ageing 1993:22:138-153.
14. Harrington CR, Wischik CM, McArthur FK, Taylor GA, Edwardson JA, Candy JM: Alzheimer's disease-like changes in tau protein processing: Association with aluminium accumulation in brains of renal dialysis patients. Lancet 1994;343:993-997.
15. Clauberg M, Joshi JG: Regulation of serine protcasc activity by aluminium: Implications for Alzheimer’s disease. Proc Natl Acad Sci USA 1993;90:1009-1012.
16. Nandy K: Immunologic factors: in Reisbcrg B (ed): Alzheimer's Disease. The Standard Reference. London/New York. MacMillan, 1983, pp 135-138.
17. McGecr PL, Akiyama H, Itagaki S, McGeer EG: Immunosystem response in Alzheimer's disease. Can J Neurol Sci 1989:16:516-527.
18. McGeer PL, McGeer EG, Kawamata T, Ya-mada T, Akiyama H: Reactions of the immune system in chronic degenerative neurological diseases. Can J Neurol Sci 1991; 18:376-379.
19. Hcinonen O, Syrjanen S, Soininen H, Talasme-nii S, Kaski M, Mantyjarvi R, Svrjanen K. Riekkinen P: Circulating immune complexes in sera from patients wiili Alzheimer's disease, multi-infarct dementia and Down's syndrome. Ncurosci Lett 1993:149:67-70.
20. Armstrong RA, Cattell RJ, Jones SA, Winsper S, Blair JA: Elevated urinary neopterin suggests immune activation in Alzheimer's disease and Down's syndrome. Ncurosci Res Comnum 1994:14:63-69.
21. Martvn CN: The epidemiology of Alzheimer's disease in relation to aluminium. Ciba Found Symp 1992:169:69-79.
22. Graves AB, While E, Koepsell TD, Reiller BV, van Belle G, Larson EB: The association between aluminium containing products and Alzheimer's disease. J Clin Epidemiol 1990:43: 35-44.
23. Ncri LC, Hewitt D: Aluminium, Alzheimer's disease and drinking water. Lancet 1991:338: 390.
24. Basun H, Forssell LG, Wellerberg L, Winblad B: Metals and trace elements in plasma and cerebrospinal fluid in normal ageing and Alzheimer's disease. J Neural Transm 1991:4: 231-258.
25. Edwardson JA, Klinowski J, Oakley AE, Perry RH, Candy JM: Aluminosilicatcs and the ageing brain: Implications for the pathogenesis of Alzheimer's disease. Ciba Found Symp 1986: 121:160-179.
26. Landsberg JP, McDonald B, Watt F: Absence of aluminium in neurilic plaque cores in Alzheimer's disease. Nature 1992;360:65-68.
27. Edwardson JA, Candy JM, Ince PG, McArthur FK, Morris CM, Oaklev AE, Taylor GA, Bjert-ncss E: Aluminium accumulation, ß-amyloid deposition and neurofibrillary changes in the central nervous system. Ciba Found Symp 1992:169:165-179.
28. Armstrong RA, Myers D, Smith CUM: The ratio of diffuse to mature beta/A4 deposits in Alzheimer’s disease varies in cases with and without pronounced congophilic angiopathy. Dementia 1993;4:251-255.
29. Perl DP, Brody AR: Alzheimer's disease: X-ray spcctrometric evidence of aluminium accumulation in neurofibrillary tangle-bearing neurons. Science 1980:208:297-299.
30. Perl DP, Pendlebury WW: Aluminium neurotoxicity: Potential role in the pathogenesis of neurofibrillary tangle formation. Can J Neurol Sei 1986:13:441-445.
31. Martin RB: Aluminum speciation in biology. Ciba Found Svmp 1992; 169:5-18.
32. Dobson CB, Templer J, Day JP, Itzltaki RF: Aluminium and Alzheimer’s disease: Sites of aluminium-binding in human neuroblastoma cells. Biochcm Soc Trans 1993:21:P32.
33. Perl DP: Relationship of Aluminium to Alzheimer’s disease. Environ Health Perspect 1985:63:149-153.
34. Crapper DR, Karlik S, de Boni U: Aluminium and other metals in senile (Alzheimer) dementia. Aging (NY) 1978;7:471-489.
35. Seil FJ, Lampert PW, Katzo I: Neurofibrillary spheroids induced by aluminium phosphate in dorsal root ganglia neurons in vitro. J Neuropa-thol Exp Neurol 1969:28:74.
36. Terry RD, Pena C: Experimental production of neurofibrillary' degeneration. J Neuropathol Exp Neurol 1965:24:200-210.
37. Grunde-Iqbal I, Wang GP, Iqbal K, Wisniewski HM: Alzheimer's paired helical filaments: Identification of polypeptides with monoclonal antibodies. Acta Neuropathol 1985,68:279-283.
38. Arieff AI: Aluminium and the pathogenesis of dialysis encephalopathy. Am J Kidney Dis 1985:6:317-321.
39. Murphy CP, Cox RL, Harden EA, Stevens DA, Heize MM, Herzig RH: Encephalopathy and seizures induced by intravesical alum irrigations. Bone Marrow Transplant 1992; 10:383-385.
40. Candy JM, McArthur FK, Oakley AE, Taylor GA, Chen CPL, Mountfort SA, Thompson JE, Chalkcr PR, Bishop HE, Beyreuthcr K, Perry G, Ward MK, Martyn CN, Edwardson JA: Aluminium accumulation in relation to senile plaque and neurofibrillary tangle formation in the brains of patients with renal failure. J Neurol Sei 1992;107:210-218.
41. MAFF: Aluminium in Food. 39th Report. London, HMSO. 1993.
42. Bowen DJ, Gunn AM, Lacey RF, Itzhaki RF: Aluminium in drinking water and Alzheimer's disease - Final report. Report FR 0376, Foundation of Water Research, 1993.
43. Gregor JL: Dietary and other sources of aluminium uptake; in Chadwick DJ, Whelan J (eds): Aluminium in Biology and Medicine. Ciba Found Symp. New York, Wiley, 1992, vol 169, pp 26-49.
44. Armstrong RA, Anderson J, Cowburn JD, Cox J, Blair JA: Aluminium administered in drinking water but not in the diet influences biopterin metabolism in the rodent. Biol Chcrn Hoppe Scyler 1992;373:1075-1078.
45. Benno UL Becker GJ: Gastrointestinal absorption of aluminium. Am J Kidney Dis 1985:6: 302-305.
46. van der Voet GB: Intestinal absorption of aluminium; in Chadwick DJ. Whelan J (eds): Aluminium in Biology and Medicine. Ciba Foundation Symp. New York. Wiley, 1992, vol 169, pp 109-117.
47. de Jong G, Dijk JP, Eijk HG van: The biology of transferrin. Clin Chim Acta 1990:190:1-46.
48. Trapp G: Plasma aluminium is bound to transferrin. Life Sci 1983:33:311-316.
49. 3+. Clin Chem 1987;33:405-407.
50. Hodgkins PS: Reduced metal transferrin binding in neurological diseases: PhD Thesis, University of Aston. 1992.
51. Hodgkins PS, Prasher V, Farrar G, Armstrong RA, Sturman S, Corbett J, Blair JA: Reduced transferrin binding in Down’s syndrome: A route to senile plaque formation and dementia. Ncuroreport 1993:5:21-24.
52. van Rensburg SJ, Carstens ME, Potocnik FCV, Aucamp AK, Talzaard JJF, Koch KR: Membrane fluidity of platelets and erythrocytes in patients with Alzheimer’s disease and the effect of small amounts of aluminium. Neurochem Res 1992:17:825-829.
53. Graziani LJ, Kaplan RK, Escriva A, Katzman R: Calcium flux into CSF during ventricular and ventriculocisternal perfusion. Am J Physiol 1967;213:629-636.
54. Deloncle R, Guillard O, Clanet F, Courtois P, Pirion A: Aluminium transfer as glutamate complex through the blood brain barrier. Biol Trace Elem Res 1990:25:39-45.
55. Mann DMA: The neuropathology of Alzheimer's disease: A review with pathogenetic, ae-tiological and therapeutic considerations. Mech Ageing Dev 1985,31:213-255.
56. Banks WA, Kastin AJ: Aluminium alters the permeability of the blood-brain barrier to some non peptides. Neuropharmacology 1985:24: 407-412.
57. Taylor GA, Morris CM, Fairbaim AF, Candy JM, Edwardson JA: Transferrin-gallium binding in Alzheimer's disease. Lancet 1991:338: 1394-1395.
58. Roskams AJ, Connor JR: Aluminium access to the brain: A role for transferrin and its receptor. Proc Nall Acad Sei USA 1990:87:9024-9027.
59. Armstrong RA: Is the clustering of neurofibrillary tangles in Alzheimer's patients related to the cells of origin of specific corticocortical projections? Ncurosci Lett 1990; 160:57-60.
60. Pullen RGL, Candy JM, Morris CM, Taylor G, Keith AB, Edwardson JA: Gallium 67 as a potential marker for aluminium transport in the rat brain: Implications for Alzheimer’s disease. J Neurochem 1990:55:251-259.
61. Octave JN, Schneider YJ, Trouel A, Crichton RR: Iron uptake and utilization by mammalian cells. Trends Biochem Sci 1993:217-220.
62. Rasey JS, Nelson NJ, Larson SM: Tumor cell toxicity of stable gallium nitrate: Enhancement by transferrin and protection by iron. Eur J Cancer Clin Oncol 1982;16:661-668.
63. Klatzo I, Wisniewski HM, Streicher E: Experimental production of neurofibrillary degeneration. J Neuropathol Exp Neurol 1965:24:187-199.
64. Crapper DR, Quittkat S, Krishnan SS: Intranuclear aluminium content in Alzheimer’s disease, dialysis encephalopathy and experimentally induced aluminium encephalopathy. Acta Neuropathol 1980;50:19-24.
65. Shi B, Huang A: Muminium uptake by neuroblastoma cells. J Neurochem 1989:28:3911 -3915.
66. Leininger JR, Farrell RL, Johnson GR: Acute lung lesions due to zirconium and aluminium compounds in hamsters. Arch Pathol Lab Med 1977:101:543-549.
67. Glick JL: Dementias: The role of magnesium deficiency and a hypothesis concerning the pathogenesis of Alzheimer’s disease. Med Hypotheses 1990;31:211-225.
68. Williams RJP: Aluminium in biology: An introduction; in Chadwick DJ, Whelan J (eds): Aluminium in Biology and Medicine. Ciba Found Symp. New York, Wiley, 1992, vol 169, PP 1-4.
69. Armstrong RA, Winsper SJ, Blair JA: Hypothesis: Is Alzheimer's disease a metal-induced immune disorder? Neurodegcncration 1995:4: 107-111.
70. Love SM, Saitoh T, Ouyada S, Cole GM, Terry RD: Alz 50, ubiquitin and lau immunoreactivi-ty of neurofibrillary tangles. Pick bodies and Lewy bodies. J Neuropathol Exp Neurol 1988; 47:393-405.
71. Dustin P, Brion J-P, Flament-Durand J: What’s new in the pathology of the neuronal cyloskeleion: The significance of neurofibrillary tangles. Pathol Res Pract 1992:188:248-253.
72. Lee G, Cowan N, Kirschner M: The primary structure and heterogeneity of tau protein from mouse brain. Science 1988:239:285-288.
73. erk converts tau into a PHF-like form as found in Alzheimer’s disease. Biochem Biophys Res Commun 1993; 193:639-647.
74. Caputo CB, Sygowski LA, Scott CW, Evange-lista-Sobcl 1R: Role of tau in the polymerization of peptides front ß-amyloid precursor protein. Brain Res 1992;597:227-232.
75. Hanger DP, Brion JP, Gallo JM, Cairns NJ, Luthert PJ, Anderton BH: Tau in Alzheimer’s disease and Down’s syndrome is insoluble and abnormally phosphorylated. Biochem J 1991; 275:99-104.
76. Shin RW, Iwaki T, Kitamoto T, Sato Y, Tatei-shi J: Massive accumulation of modified tau and severe depletion of normal tau characterize the cerebral cortex and white matter of Alzheimer's disease. Am J Pathol 1992; 140:937-944.
77. Delacourte A, Flament S, Dike EM, Hublan P, Sablonniere P, Hemon B, Sherrer V, Defossez A: Pathological proteins tau 64 and 69 are superficially expressed in the somatodendritic domain of the degenerating cortical neurons in Alzheimer's disease. Acta Neuropathol 1990: 80:111-117.
78. Guy SP, Jones D, Mann DMA, Itzhaki RF: Human neuroblastoma cells treated with aluminium express an epitope associated with Alzheimer's disease neurofibrillary tangles. Neurosci Lett 1991;121:166-168.
79. Shin RW, Lee VM, Trojanowski JQ: Aluminium modifies the properties of Alzheimer's disease PHFt proteins in vivo and in vitro. J Neurosci 1994;14:7221-7233.
80. Suzuki N, Cheung TT, Cai X-D, Odaka A, Otvos L Jr, Eckmann C, Golde TE, Younkin SG: An increased percentage of long amyloid P protein secreted by familial amyloid P protein precursor (PAPP717) mutants. Science 1994; 264:1336-1340.
81. Wisniewski T, Ghiso J, Frangione B: Alzheimer’s disease and soluble Ap. Neurobiol Aging 1994;15:143-152.
82. Kawahara M, Muramoto K, Kobayashi K, Mori H, Koruda Y: Aluminium promotes the aggregation of Alzheimer's amyloid P-protein in vitro. Biochem Biophys Res Commun 1994; 198:531-535.
83. Regland B, Gottfries CG: The role of amyloid P-protein in Alzheimer's disease. Lancet 1992; 340:467-469.
84. Tabaton M, Cammarata S, Mancardi G, Ma-netto V, Antilio-Gambetti L, Perry G, Gambet-ti P: Ultrastructural localisation of P-amyloid, tau and ubiquitin epitopes in extracellular neurofibrillary tangles. Proc Natl Acad Sci USA 1991;88:2098-2102.
85. Pearson RCA, Esiri MM, Hioms RW, Wilcock GFC, Powell TPS: Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer’s disease. Proc Natl Acad Sci USA 1985;82:4531-4534.
86. Armstrong RA, Myers D, Smith CUM: The spatial patterns of p/A4 deposit subtypes in Alzheimer's disease. Acta Neuropathol 1993;86:36-41.
87. Rogers J, Luber-Narod J: Immune actions in nervous system: Brief rev iew with special emphasis on Alzheimer's disease. Drug Dev Res 1988;15:227-235.
88. Ishii T, Haga S: Immuno-electron microscopic localisation of immunoglobulins in amyloid fibrils of senile plaques. Acta Neuropathol 1976: 20:372-378.
89. Eikelenboom P, Stam FC: Immunoglobulin and complement factors in senile plaques. Acta Neuropathol 1982;57:239-242.
90. Walford RL, Fortoul T: Histocompatibility locus antigens in Alzheimer’s disease; in Reisberg B (ed): Alzheimer’s Disease. The Standard Reference. London/New York, MacMillan. 1983. pp 166-169.
91. Cohen D, Eisdorfer C, Walford R: Histocompatibility antigens (HLA) and patterns of cognitive loss in dementia of the Alzheimer type. Neurobiol Aging 1982;2:277-280.
92. Henschke PJ, Bell DA, Cape RDT: Alzheimer’s disease and HLA. Tissue Antigens 1978; 12:132-135.
93. Kosuda LL, Greiner DL, Bigazzi PE: Mercury-induced renal autoimmunity: Changes in RT6+ T-lymphocvtes of susceptible and resistant rats. Environ Health Perspect 1993:101: 178-185.
94. Epstein PE, Dauber JH, Rossman MD, Dani-ele RP: Bronchoalveolar lavage in a patient with chronic berylliosis: Evidence for hypersensitivity pneumonitis. Ann Intern Med 1982; 57:213-216.
95. Bartter T, Irwin RS, Abraham JL, Dascal A, Nash G, Himmelstain JS, Jederlinc PJ: Zirconium compound-induced pulmonary fibrosis. Arch Intern Med 1991;151:1197-1201.
96. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta KG: Adjuvants-a balance between toxicity and adjuvanticity. Vaccine 1993;11:293-306.
97. Ramanathan VD, Badenoch-Jones P, Turk JL: Complement activation by aluminium and zirconium compounds. Immunology 1979;37:881-888.
98. Kishimoto T, Ishizaka K: Regulation of antibody response in vitro VI. Carrier-specific helper cells for IgG and IgF antibody responses. J Immunol 1974:1 11:720-732.
99. Reiotella R, Orasy Z: Reagenic antibody production in different mouse strains. Immunology 1969;17:45-54.
100. Sarvetnick N, Fox HS: Interferon-gammaand the sexual dimorphism of auto-immunity. Mol Biol Med 1990;7:323-331.
101. McCoy KL, Noone M, Inman JK, Stutzman R: Exogenous antigens internalized through transferrin receptors activate CD4* T cells. J Immunol 1993:150:1691-1704.
102. Richeldi L, Sorrentino R, Saltini C: HLA-DPBI glutamate 69: A genetic marker of beryllium disease. Science 1993:262:242-244.
103. Liew SCK, Penfold PL, Provis JM, Madigan MC, Billson FA: Modulation of MHC class II expression in the absence of lymphocytic infiltrates in Alzheimer's retinae. J Neuropathol Exp Neurol 1994:53:150-157.
104. Weiss G, Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, Semenitz E, Dierich MP, Wachter H: Neopterin modulates toxicity mediated by reactive oxygen and chloride species. FEBS Lett 1993:321: 89-92.
105. Wallace W, Aiders ST, Gotlib J, Bragin V, Sugar J, Gluck R, Shea PA, Davis KL, Harou-tunian V: Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation. Proc Natl Acad Sci USA 1993;90:8712-8716.
106. Ohgami T, Kitamoto T, Shin RW, Kaneko Y, Ogomori K, Takeishi J: Increased senile plaques without microglia in Alzheimer's disease. Acta Neuropathol 1991;81:242-247.
107. Mann DMA, Younis N, Jones D, Stoddart RW: The time course of pathological events in Down's syndrome with particular reference to the involvement of microglial cells and deposits of β/A4. Neurodegeneration 1992;1:201-215.